NeuroNews’ Post

Retriever Medical ���𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗿𝗼𝘂𝗻𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝘁𝗵𝗿𝗼𝗺𝗯𝗲𝗰𝘁𝗼𝗺𝘆 𝘀𝘆𝘀𝘁𝗲𝗺 💰 Retriever Medical is seeking $10M in Series A funding to drive their novel thrombectomy system for treating pulmonary embolism (PE) and deep vein thrombosis (DVT) through FDA clearance and clinical studies. 🔥 They've raised $3.5M to date and are partnering with leaders like Resonetics and Midwest Interventional Systems, Inc. 🩸 Their unique dual-basket, drug-eluting mechanical thrombectomy device paired with aspiration and reinfusion is poised to make a major impact in the rapidly growing venous thromboembolism market. 📈 The venous thromboembolism treatment market has huge potential - with the likes of Inari Medical projecting $575M in revenue this year while only tapping 25% of the available patient population who are currently treated with anticoagulants. #Thrombectomy #MechanicalThrombectomy #Vascular #MedTech

Boston Scientific to acquire Relievant Medsystems, Inc. for $850 million. The number of companies attempting to conquer the chronic pain burden with spinal cord stimulation (SCS) globally continues to grow, fail, rebrand, acquire, and redefine the space. Medtronic announced 510k of it's Inceptiv closed-loop system earlier this month in Europe, further validating that technology as the future of SCS. Meanwhile, Saluda Medical continues to revolutionize the arena with Evoke, the first-to-market closed-loop system. With SmartSCS it can automatically adjust stimulation to maintain precise and consistent neural activation to the spinal cord for the treatment of intractable low back and leg pain. Patients want to have options. They can now test drive several, using data to help decide what works best for their lifestyle. #spinalcordstimulation #neuromodulation #acquisition

👍 InnovHeart announced the first trans-septal clinical trial implant of its proprietary Saturn transcatheter mitral valve, which led to excellent hemodynamic results for the patient. The procedure was part of system’s ongoing European clinical trial, the CASSINI-EU study. 👏Best of luck in the trial to the medical team, CEO David Wilson, and CTO Giovanni Righini! 🔗 Learn more: https://lnkd.in/e4RXksht 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/echiXdGC #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions

🚀 Irish medical device firm Ceroflo announced it has raised €6.4 million in investment-round funding, to help develop its SubMax device—a novel stent intended to “revolutionise” intracranial atherosclerotic disease treatments. 📣 CEO Chloe Brown commented: "We are approaching the problem with a unique understanding of the challenges and are designing the technology with clinicians who have more than 50 years’ collective experience treating this disease. [...] This €6.4 million investment will enable Ceroflo to bring the SubMax stent to 30 patients in a first-in-human trial—a significant value inflection point. It will also allow us to provide a platform to support further US and Japanese regulatory studies.” 👉 Read more: https://lnkd.in/di884E5J 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dJqiv63c #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #Surgeons #GuidedSolutions #Investment #FundingRound

Over a decade ago #EPeeps started a journey to reduce fluoro w ICE & mapping system, with small studies showing safety. Few years ago #RealAF registry was born w dozens of #Epeeps collaborating to collect RWE - which has now confirmed the safety of a low/Zero fluoro workflow leading to the FDA approval. It is very important to acknowledge that hundreds of people have been involved in this journey and effort to get to the FDA approval. 100+ electrophysiologists at 50 institutions have engaged in this #RBC (Registry-Based Collaborative) collecting #RWE. Research and quality staff from institutions in 36 states have been involved. And Biosense Webster chose to support one of the largest #RWE efforts in the field of Electrophysiology with close collaboration. The FDA approval highlights the importance of collaboration among physicians, research and quality coordinators and industry. It evidences how much ablation has progressed. And confirms benefits of the Heart Rhythm Clinical Research Solutions Registry-based collaborative model!

Check out this recent interview of Adam Hattan our VP of Marketing & Business Development, by Anne Staylor of SmartTRAK / BioMedGPS, LLC discussing the latest news on #Route92Medical and SUMMIT MAX, the first randomized controlled trial to evaluate safety and effectiveness of "super-bore" 0.088" aspiration catheters. Read more to hear about how #Route92Medical is advancing #neurointervention.

Discover the Latest in the MedTech World! 🩺 💡 Revitalise your week with our essential update on all things MedTech! Globus Medical launched its second major paediatric scoliosis product: The Marvel growing rod system; it is designed to obtain and maintain correction in paediatric scoliosis patients for early-onset Scoliosis. https://lnkd.in/gviYn7P4 Quest has joined the advances in drug treatments for Alzheimer’s disease. The clinical testing giant has put forward a blood test designed to help gauge a person’s levels of beta-amyloid—one of the hallmarks of the neurodegenerative condition—and it’s now making it available directly to consumers. https://lnkd.in/eJNy_zHi Vicarious Surgical Inc. expects to perform a ventral hernia repair, the first procedure on a patient using its system, in mid-2024. Based on guidance and input from the FDA, Vicarious plans to complete a clinical trial with a total of 30 to 60 patients, including people from outside the United States, CEO Adam Sachs said on the company’s earnings call on Thursday. https://lnkd.in/gMur2sAW GE HealthCare warned that the sensors could limit the effectiveness of cardiac defibrillation, expose patients to electrical currents, or give inaccurate blood oxygen readings. The US FDA categorised GE HealthCare’s recall of malfunctioning oxygen sensors as a Class I event, the agency said in a Friday notice. https://lnkd.in/gNuZze7e Thermo Fisher Scientific announced it would cut costs by an additional $450 million in 2023, citing a more difficult macroeconomic situation in the year's first half. According to the company, customers in the biopharmaceutical and other industries showed increased caution in the second quarter. https://lnkd.in/gceSMDBK Baxter International Inc. expects hospital spending to increase in the year's second half amid rising procedure volumes and a stabilising supply chain. The company is moving forward with plans to spin out its kidney care and acute therapies units and sell its biopharma solutions business amid a broader reorganisation. https://lnkd.in/dMZxf3Vj #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends

Results from a Phase 2 clinical trial suggest that although the 8 mg dose of aflibercept did not achieve the primary efficacy endpoint of eyes with the absence of intraretinal and subretinal fluid in the central subfield at week 16, it may offer additional therapeutic benefits over the standard 2 mg dose for the treatment of neovascular age-related macular degeneration (nAMD). Read the full article here ⤵️ #maculardegeneration #macular #aflibercept

The Phase 3 PULSAR trial demonstrated that aflibercept 8 mg provides greater therapeutic benefits and an extended injection interval, with equivalent safety, compared to aflibercept 2 mg in the treatment of neovascular age-related macular degeneration (nAMD), according to data presented at ASRS 2023. Read the complete article below ⤵️ #maculardegeneration #agerelatedmaculardegeneration #ASRS2023

#VTAK Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a U.S. based medical device company focused on novel electrophysiology products, announced that VIVO was used for the first time on a pediatric patient in Turkey. The Company recently announced its new distribution partnership with Ege Artimi in Turkey in January. Catheter Precision's CEO, David Jenkins, said, "VIVO is an excellent choice for pre-procedure planning, especially in pediatric patients. VIVO is non-invasive and used prior to ventricular ablations, meaning that it can provide the physician with additional information specific to each patient and because it is non-invasive there is no additional risk when it is utilized. The utilization of VIVO in delicate patient populations like this continues to show the flexibility and many benefits of this innovative product." https://lnkd.in/eMNrtFrs